Pre-made Oportuzumab biosimilar ( scFv, anti-EPCAM therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-408
Anti-EPCAM therapeutic antibody (Pre-made Oportuzumab biosimilar,scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-EPCAM therapeutic antibody (Pre-made Oportuzumab biosimilar,scFv)|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies|
|Conditions Active||Bladder cancer;Head and neck cancer|
|Conditions Discontinued||Liver cancer;Ovarian cancer|